During differentiation, neurons progressively restrict their fate repressing the expression of specific genes. Here we describe the involvement in such developmental steps of the methyl-CpG binding protein 2 (MeCP2), an epigenetic factor that participates to chromatin folding and transcriptional regulation. We previously reported that, due to transcriptional impairments, the maturation of Mecp2 null neurons is delayed. To evaluate whether this could stem from altered progenitors proliferation and differentiation, we investigated whether lack of Mecp2 affects these features both in vitro and in vivo. We show that in Mecp2 null embryonic cortexes the expression of genes defining the identity of proliferating neuroprogenitors is enriched and that their permanence in the G1 phase is prolonged. Moreover, the number of cells transitioning from a stage of maturation to a more mature one is increased in Mecp2 null embryonic cortices, in line with the central role of G1 for cell identity refinement. We thus suggest that, possibly due to the lack of proper transcriptional control normally exerted by Mecp2, fate refinement is impaired in developing null cells. We propose that the maturation delay affecting the developing Mecp2 null cortex originates, at least in part, from deranged mechanisms of cell fate refinement.

Download full-text PDF

Source
http://dx.doi.org/10.1093/cercor/bhx360DOI Listing

Publication Analysis

Top Keywords

mecp2 null
16
fate refinement
12
methyl-cpg binding
8
binding protein
8
mecp2
8
protein mecp2
8
cell fate
8
null embryonic
8
null
5
lack methyl-cpg
4

Similar Publications

Rett syndrome (RTT) is a severe neurodevelopmental disorder primarily caused by mutations in the methyl-CpG binding protein 2 () gene. Despite advancements in research, no cure exists due to an incomplete understanding of the molecular effects of MeCP2 deficiency. Previous studies have identified impaired tropomyosin receptor kinase (Trk) neurotrophin (NTP) signaling and mitochondrial redox imbalances as key drivers of the pathology.

View Article and Find Full Text PDF
Article Synopsis
  • * Research indicates that the synthetic compound Trofinetide and nerve growth factor (rhNGF) may provide therapeutic benefits, as seen in both cell cultures and in vivo studies with mice lacking MECP2.
  • * Positive results from treatments with rhNGF showed improved cognitive and motor abilities in both male and female mouse models of Rett syndrome, with further analysis planned to explore underlying molecular mechanisms.
View Article and Find Full Text PDF
Article Synopsis
  • - RTT is a neurodevelopmental disorder first described in 1966, with significant advancements in understanding and therapy starting with the identification of the MECP2 gene in 1999, which is crucial for diagnosing and understanding the condition.
  • - The NIH funded a comprehensive RTT Natural History Study in 2003, collecting vital clinical data from a large RTT population that laid the groundwork for developing therapies and clinical trials.
  • - Collaboration with the International Rett Syndrome Foundation has facilitated research initiatives, leading to findings on RTT characteristics, comorbidities, and the development of severity measures that are essential for future clinical applications.
View Article and Find Full Text PDF

Human microglial cells as a therapeutic target in a neurodevelopmental disease model.

Stem Cell Reports

August 2024

University of California, San Diego, School of Medicine, Department of Pediatrics/Rady Children's Hospital San Diego, Department of Cellular & Molecular Medicine, La Jolla, CA 92037, USA; University of California, San Diego, Kavli Institute for Brain and Mind, Center for Academic Research and Training in Anthropogeny (CARTA), La Jolla, CA 92093, USA. Electronic address:

Article Synopsis
  • Microglia, although typically known for their immune functions in the central nervous system, also play crucial roles in brain development that are not yet fully understood, especially in humans.
  • Researchers used human microglia-like cells with a deleted MECP2 gene to study its impact, discovering that this disruption led to significant issues in cell functions like phagocytosis and synapse formation.
  • A drug called ADH-503 was found to enhance phagocytosis and restore normal synapse formation, offering potential new treatment options for conditions linked to MECP2 abnormalities in mice.
View Article and Find Full Text PDF

CRL4 E3 ubiquitin ligase targets MeCP2 for degradation to prevent DNA hypermethylation and ensure normal transcription in growing oocytes.

Cell Mol Life Sci

April 2024

Assisted Reproduction Unit, Department of Obstetrics and Gynecology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, 310016, China.

The DNA methylation is gradually acquired during oogenesis, a process sustained by successful follicle development. However, the functional roles of methyl-CpG-binding protein 2 (MeCP2), an epigenetic regulator displaying specifical binding with methylated DNA, remains unknown in oogenesis. In this study, we found MeCP2 protein was highly expressed in primordial and primary follicle, but was almost undetectable in secondary follicles.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!